{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T16:39:56Z","timestamp":1721061596308},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,23]],"date-time":"2018-06-23T00:00:00Z","timestamp":1529712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00280-018-3629-1","type":"journal-article","created":{"date-parts":[[2018,6,23]],"date-time":"2018-06-23T06:46:38Z","timestamp":1529736398000},"page":"421-428","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients"],"prefix":"10.1007","volume":"82","author":[{"given":"Sreenivasulu","family":"Palugulla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panneer","family":"Devaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil K.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayanthi","family":"Mathaiyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,23]]},"reference":[{"key":"3629_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.critrevonc.2011.12.007","volume":"83","author":"EJ Hill","year":"2012","unstructured":"Hill EJ, Nicolay NH, Middleton MR, Sharma RA (2012) Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research? Crit Rev Oncol Hematol 83:353\u2013387","journal-title":"Crit Rev Oncol Hematol"},{"key":"3629_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00280-016-3067-x","volume":"78","author":"KN Pilanc\u0131","year":"2016","unstructured":"Pilanc\u0131 KN, Saglam S, Okyar A, Yucel S, Pala-Kara Z, Ordu C et al (2016) Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: a phase II Brunch regimen study. Cancer Chemother Pharmacol 78:143\u2013150","journal-title":"Cancer Chemother Pharmacol"},{"key":"3629_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00280-014-2407-y","volume":"73","author":"Y Chao","year":"2014","unstructured":"Chao Y, Hsieh J-S, Yeh H-T, Su Y-C, Wu C-C, Chen J-S et al (2014) A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemother Pharmacol 73:799\u2013806","journal-title":"Cancer Chemother Pharmacol"},{"key":"3629_CR4","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"3629_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000328767","volume":"80","author":"H Isayama","year":"2011","unstructured":"Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H et al (2011) Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Oncology 80(1\u20132):97\u2013101","journal-title":"Oncology"},{"key":"3629_CR6","doi-asserted-by":"crossref","first-page":"76298","DOI":"10.18632\/oncotarget.11818","volume":"7","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhuang R, Yu Y, Yu S, Hou J, Ji Y et al (2016) Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget 7:76298\u201376307","journal-title":"Oncotarget"},{"key":"3629_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.bjc.6602966","volume":"94","author":"A Demols","year":"2006","unstructured":"Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E et al (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94:481\u2013485","journal-title":"Br J Cancer"},{"key":"3629_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/toxics3020187","volume":"3","author":"AA Argyriou","year":"2015","unstructured":"Argyriou AA (2015) Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Toxics 3:187\u2013197","journal-title":"Toxics"},{"key":"3629_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/CMAR.S44261","volume":"6","author":"AA Argyriou","year":"2014","unstructured":"Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP (2014) Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 6:135\u2013147","journal-title":"Cancer Manag Res"},{"key":"3629_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","volume":"33","author":"FH Hausheer","year":"2006","unstructured":"Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15\u201349","journal-title":"Semin Oncol"},{"key":"3629_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","volume":"63","author":"SB Park","year":"2013","unstructured":"Park SB, Goldstein D, Krishnan AV, Lin CS-Y, Friedlander ML, Cassidy J et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63:419\u2013437","journal-title":"CA Cancer J Clin"},{"key":"3629_CR12","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00520-014-2242-z","volume":"22","author":"AJM Beijers","year":"2014","unstructured":"Beijers AJM, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22:1999\u20132007","journal-title":"Support Care Cancer"},{"key":"3629_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/mus.10559","volume":"29","author":"TJ Lehky","year":"2004","unstructured":"Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387\u2013392","journal-title":"Muscle Nerve"},{"key":"3629_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.critrevonc.2013.08.009","volume":"89","author":"M Sereno","year":"2014","unstructured":"Sereno M, Guti\u00e9rrez-Guti\u00e9rrez G, G\u00f3mez-Raposo C, L\u00f3pez-G\u00f3mez M, Merino-Salvador M, T\u00e9bar FZ et al (2014) Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol 89:166\u2013178","journal-title":"Crit Rev Oncol Hematol"},{"key":"3629_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.5414\/CPP48729","volume":"48","author":"M Inada","year":"2010","unstructured":"Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A et al (2010) Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 48:729\u2013734","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3629_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.canep.2010.02.008","volume":"34","author":"M Kanai","year":"2010","unstructured":"Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T et al (2010) Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 34:189\u2013193","journal-title":"Cancer Epidemiol"},{"key":"3629_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mdt546","volume":"25","author":"A Custodio","year":"2014","unstructured":"Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J et al (2014) Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 25:398\u2013403","journal-title":"Ann Oncol"},{"key":"3629_CR18","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/cncr.26614","volume":"118","author":"H-H Won","year":"2012","unstructured":"Won H-H, Lee J, Park JO, Park YS, Lim HY, Kang WK et al (2012) Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118:2828\u20132836","journal-title":"Cancer"},{"key":"3629_CR19","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1002\/cncr.28234","volume":"119","author":"AA Argyriou","year":"2013","unstructured":"Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J et al (2013) Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer 119:3570\u20133577","journal-title":"Cancer"},{"key":"3629_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/sj.bjc.6605134","volume":"101","author":"DM Kweekel","year":"2009","unstructured":"Kweekel DM, Antonini NF, Nortier JWR, Punt CJA, Gelderblom H, Guchelaar H-J (2009) Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br J Cancer 101:357\u2013362","journal-title":"Br J Cancer"},{"key":"3629_CR21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s12038-012-9256-9","volume":"37","author":"R Tamang","year":"2012","unstructured":"Tamang R, Singh L, Thangaraj K (2012) Complex genetic origin of Indian populations and its implications. J Biosci 37:911\u2013919","journal-title":"J Biosci"},{"key":"3629_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2013-305334","volume":"85","author":"R Velasco","year":"2014","unstructured":"Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P et al (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85:392\u2013398","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3629_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/cncr.27732","volume":"119","author":"AA Argyriou","year":"2013","unstructured":"Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M et al (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119:438\u2013444","journal-title":"Cancer"},{"key":"3629_CR24","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/nar\/3.9.2303","volume":"3","author":"N Blin","year":"1976","unstructured":"Blin N, Stafford DW (1976) A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 3:2303\u20132308","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"3629_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/bib\/3.2.146","volume":"3","author":"CM Lewis","year":"2002","unstructured":"Lewis CM (2002) Genetic association studies: design, analysis and interpretation. Br Bioinform 3(2):146\u2013153","journal-title":"Br Bioinform"},{"key":"3629_CR26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2471\/BLT.15.163998","volume":"94","author":"J Robertson","year":"2016","unstructured":"Robertson J, Barr R, Shulman LN, Forte GB, Magrini N (2016) Essential medicines for cancer: WHO recommendations and national priorities. Bull World Health Organ 94:735\u2013742","journal-title":"Bull World Health Organ"},{"key":"3629_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1200\/JCO.2006.08.1844","volume":"25","author":"A Ruzzo","year":"2007","unstructured":"Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D et al (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25:1247\u20131254","journal-title":"J Clin Oncol"},{"key":"3629_CR28","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-05-2076","volume":"12","author":"T Lecomte","year":"2006","unstructured":"Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot M-A (2006) Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12:3050\u20133056","journal-title":"Clin Cancer Res"},{"key":"3629_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12017-011-8150-1","volume":"13","author":"G Wu","year":"2011","unstructured":"Wu G, Cao J, Peng C, Yang H, Cui Z, Zhao J et al (2011) Temporal and spatial expression of cyclin H in rat spinal cord injury. Neuromol Med 13:187\u2013196","journal-title":"Neuromol Med"},{"key":"3629_CR30","first-page":"572","volume":"4","author":"G Lolli","year":"2005","unstructured":"Lolli G, Johnson LN (2005) CAK\u2014cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle Georget Tex 4:572\u2013577","journal-title":"Cell Cycle Georget Tex"},{"key":"3629_CR31","unstructured":"Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding\u2014PubMed\u2014NCBI [Internet]. [cited 2017 Aug 28]. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16797073"},{"key":"3629_CR32","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/art.1780370917","volume":"37","author":"AI Blakemore","year":"1994","unstructured":"Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW (1994) Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 37:1380\u20131385","journal-title":"Arthritis Rheum"},{"key":"3629_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.bjoms.2014.05.010","volume":"52","author":"A Murali","year":"2014","unstructured":"Murali A, Nalinakumari KR, Thomas S, Kannan S (2014) Association of single nucleotide polymorphisms in cell cycle regulatory genes with oral cancer susceptibility. Br J Oral Maxillofac Surg 52:652\u2013658","journal-title":"Br J Oral Maxillofac Surg"},{"key":"3629_CR34","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/annonc\/mdw074","volume":"27","author":"M Kanai","year":"2016","unstructured":"Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D et al (2016) Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Ann Oncol 27:1143\u20131148","journal-title":"Ann Oncol"},{"key":"3629_CR35","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/jco.2005.23.16_suppl.3509","volume":"23","author":"A Grothey","year":"2005","unstructured":"Grothey A, McLeod HL, Green EM, Sargent DJ, Fuchs C, Ramanathan RK et al (2005) Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. J Clin Oncol 23:3509","journal-title":"J Clin Oncol"},{"key":"3629_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-013-2194-x","volume":"72","author":"Z Peng","year":"2013","unstructured":"Peng Z, Wang Q, Gao J, Ji Z, Yuan J, Tian Y et al (2013) Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother Pharmacol 72:305\u2013314","journal-title":"Cancer Chemother Pharmacol"},{"key":"3629_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/FPC.0b013e32834300fb","volume":"21","author":"A Cobos","year":"2011","unstructured":"Cobos A, S\u00e1nchez P, Aguado J, Carrasco JL (2011) Methodological quality in pharmacogenetic studies with binary assessment of treatment response: a review. Pharmacogenet Genomics 21:243\u2013250","journal-title":"Pharmacogenet Genomics"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3629-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3629-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3629-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T05:49:58Z","timestamp":1604468998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3629-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,23]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3629"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3629-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,23]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the local institute ethics committee (Reg.no: ECR\/342\/Inst\/PY\/2013), JIPMER as well as JIPMER Scientific Advisory Committee (no. JSAC 15\/06\/2014) and was conducted in accordance with the ethical standards of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Written informed consent, from all the patients, was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"We have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}